Logo video2dn
  • Сохранить видео с ютуба
  • Категории
    • Музыка
    • Кино и Анимация
    • Автомобили
    • Животные
    • Спорт
    • Путешествия
    • Игры
    • Люди и Блоги
    • Юмор
    • Развлечения
    • Новости и Политика
    • Howto и Стиль
    • Diy своими руками
    • Образование
    • Наука и Технологии
    • Некоммерческие Организации
  • О сайте

Скачать или смотреть NIAID trial of remdesivir met its 'primary goal': Gilead

  • CNBC Television
  • 2020-04-29
  • 4826
NIAID trial of remdesivir met its 'primary goal': Gilead
Squawk on the StreetCNBCbusiness newsfinance stockstock marketnews channelnews stationbreaking newsus newsworld newscablecable newsfinance newsmoneymoney tipsfinancial newsstock market newsstocks
  • ok logo

Скачать NIAID trial of remdesivir met its 'primary goal': Gilead бесплатно в качестве 4к (2к / 1080p)

У нас вы можете скачать бесплатно NIAID trial of remdesivir met its 'primary goal': Gilead или посмотреть видео с ютуба в максимальном доступном качестве.

Для скачивания выберите вариант из формы ниже:

  • Информация по загрузке:

Cкачать музыку NIAID trial of remdesivir met its 'primary goal': Gilead бесплатно в формате MP3:

Если иконки загрузки не отобразились, ПОЖАЛУЙСТА, НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если у вас возникли трудности с загрузкой, пожалуйста, свяжитесь с нами по контактам, указанным в нижней части страницы.
Спасибо за использование сервиса video2dn.com

Описание к видео NIAID trial of remdesivir met its 'primary goal': Gilead

CNBC's Meg Tirrell reports on the latest trial results on remdesivir, which was said to meet its 'primary goal' in the treatment of coronavirus.

Gilead Sciences said Wednesday preliminary results of a coronavirus drug trial showed at least 50% of patients treated with a five-day dosage of remdesivir improved and more than half were discharged from the hospital within two weeks.

The company also said another trial by the National Institute of Allergy and Infectious Diseases met its main goal. It did not provide further details, however.

Later Wednesday, White House health advisor Dr. Anthony Fauci said NIAID’s remdesivir drug trial, which enrolled about 800 patients, showed “quite good news” and that the drug would set a new standard of care for Covid-19 patients. Speaking to reporters from the White House, Fauci said he was told data from the trial showed a “clear-cut positive effect in diminishing time to recover.”

Shares of Gilead were up by about 6% in midday trading.

Gilead’s smaller clinical trial involved 397 patients with severe cases of Covid-19. The severe study is “single-arm,” meaning it did not evaluate the antiviral drug against a control group of patients who didn’t receive the drug.

For more coronavirus live updates:
https://www.cnbc.com/2020/04/27/coron...

For access to live and exclusive video from CNBC subscribe to CNBC PRO:
https://cnb.cx/2JdMwO7

» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic

Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook:
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC

#CNBC
#CNBC TV

Комментарии

Информация по комментариям в разработке

Похожие видео

  • О нас
  • Контакты
  • Отказ от ответственности - Disclaimer
  • Условия использования сайта - TOS
  • Политика конфиденциальности

video2dn Copyright © 2023 - 2025

Контакты для правообладателей [email protected]